In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Active Biotech AB

www.activebiotech.com

Latest From Active Biotech AB

Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis

Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.

Deals Business Strategies

Is There Life Left In Laquinimod? Teva Bows Out, But Active Biotech Interested In Brain Atrophy

The extensively evaluated immunomodulator candidate laquinimod may still have potential in the treatment of neurodegenerative diseases, says Sweden's Active Biotech, despite previous disappointing clinical trials in multiple sclerosis and Huntington's disease conducted by Teva.

 

Neurology Deals

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Laquinimod Disappoints Again, This Time In Huntington's Disease

Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.

 

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Active Biotech AB
  • Senior Management
  • Helen Tuvesson, CEO
    Hans Kolam, CFO
  • Contact Info
  • Active Biotech AB
    Phone: (46) 46 19 20 00
    Scheelevägen 22
    P.O. Box 724 Lund, SE-220 07
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register